90Y- and/or 177Lu-DOTATOC Re-Challenge in Patients with Progressive Neuroendocrine Tumors

#2962

Introduction: Most patients treated with PRRT will eventually progress. Previous studies indicated that repeated PRRT is feasible and promising.

Aim(s): To assess the efficacy of the first and second re-challenge therapy of 90Y- and/or 177Lu-DOTATOC peptide receptor-targeted radionuclide therapy (PRRT) in patients with grade 1 or 2 neuroendocrine tumors (NET).

Materials and methods: In this single center retrospective analysis, patients with grade 1 or 2 recurrent or progressive inoperable bronchial or gastroenteropancreatic NET who were admitted for re-challenge 90Y- and/or 177Lu-DOTATOC were analyzed. Re-challenge PRRT was defined as subsequent treatment after initial PRRT (repeated referral to PRRT). The time interval between treatments served as surrogate endpoint for time to progression. For re-challenge PRRT, patients underwent one 90Y-and/or 1-2 177Lu-DOTATOC treatment cycles.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Aberle S

Authors: Aberle S, Benz M, Grokovski R, Christ E, Nicolas G,

Keywords: PRRT, Re-challenge, 90Y-DOTATOC, 177Lu-DOTATOC, neuroendocrine tumor,